Shreefal Mehta is a seasoned entrepreneur with international experience in technological commercialization, as well as being an award winning biomedical scientist and engineer. Dr. Mehta co-founded a drug discovery company and merged it with a public biotech in Australia, and then managed their global business development and US operations. Cytopia closed on the largest early-stage deal in Australian biotech history with Novartis during his time there. The main drug compound being developed at Cytopia was bought by Gilead for $0.5B in cash in February 2013. Dr. Mehta also laid the path for the successful launch and marketing of a multi-million dollar analytical product for the energy/petrochemical industry in his consulting tenure with X-ray Optical Systems (purchased by Danaher for this product line in 2012). In 2006, Dr. Mehta received an award as a New York Capital Region Future Business Leader under 40.
He has served as an “Executive in Residence” at Rensselaer Polytechnic Institute’s Severino Center for Technological Entrepreneurship and has also coordinated, as Executive Director, the radical innovation research project with cohorts of Fortune 100 company executives. He is the successful author of a widely used book on commercialization of biomedical technologies and is a leader in Europe’s foremost BioBusiness course offered annually in Switzerland and sponsored by the Swiss government. He has been invited to speak at large international events such as the Indian Science Congress and the Australian Biotech Forum and has been quoted frequently as a thought leader in media such as the Economist, New Scientist, Nature Biotechnology and others.
He is currently the founding CEO of the Paper Battery Company, bringing a breakthrough energy storage technology to market. In that role, he has worked to build the company’s strategy, identified the key entry markets, built a technical team and engineering team and raised multi-million $ rounds of financing and is currently on the cusp of first commercial launch from that platform. He is also currently on the board of Pulmokine, an NIH-funded drug discovery company developing a novel inhaled drug with a disease modifying mode of action that promises to change the lives of patients in this $3.5B market by addressing a significant unmet need.
He has consulted on new ventures, strategic commercialization planning for hi-tech products, analyses of product development and value propositions over the healthcare value chain, integration of company operations across time zones, and global sourcing of technology, capital, and services.